Bruker (NASDAQ:BRKR) Releases FY 2026 Earnings Guidance

Bruker (NASDAQ:BRKR) issued an update on its FY 2026 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.100-2.150 for the period, compared to the consensus estimate of 2.120. The company issued revenue guidance of $3.5 billion-$3.6 billion, compared to the consensus revenue estimate of $3.6 billion.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on BRKR shares. Leerink Partners lifted their price objective on Bruker from $60.00 to $70.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 7th. Guggenheim boosted their price target on shares of Bruker from $50.00 to $70.00 and gave the company a “buy” rating in a research report on Monday, June 29th. JPMorgan Chase & Co. raised their price objective on shares of Bruker from $55.00 to $65.00 and gave the stock an “overweight” rating in a report on Monday, June 8th. Stifel Nicolaus set a $45.00 price target on Bruker in a research report on Friday, May 8th. Finally, Wall Street Zen upgraded Bruker from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, six have issued a Hold rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Hold” and an average target price of $56.79.

Bruker Stock Down 18.1%

Bruker stock traded down $11.61 during mid-day trading on Tuesday, hitting $52.70. The company had a trading volume of 3,879,736 shares, compared to its average volume of 2,378,590. Bruker has a 12 month low of $28.53 and a 12 month high of $65.30. The stock’s 50 day moving average price is $58.52 and its two-hundred day moving average price is $46.70. The company has a market capitalization of $8.02 billion, a PE ratio of -219.03, a price-to-earnings-growth ratio of 2.01 and a beta of 1.28. The company has a current ratio of 1.55, a quick ratio of 0.72 and a debt-to-equity ratio of 0.67.

Bruker (NASDAQ:BRKR) last released its quarterly earnings results on Wednesday, May 6th. The medical research company reported $0.31 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.23 by $0.08. Bruker had a positive return on equity of 11.60% and a negative net margin of 0.65%.The firm had revenue of $823.40 million for the quarter, compared to the consensus estimate of $795.62 million. During the same period last year, the business posted $0.47 EPS. The company’s revenue for the quarter was up 2.7% on a year-over-year basis. Bruker has set its FY 2026 guidance at 2.100-2.150 EPS. As a group, sell-side analysts anticipate that Bruker will post 2.12 earnings per share for the current fiscal year.

Bruker Announces Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, July 7th. Stockholders of record on Monday, June 22nd were paid a $0.05 dividend. This represents a $0.20 annualized dividend and a dividend yield of 0.4%. The ex-dividend date was Monday, June 22nd. Bruker’s dividend payout ratio is -83.33%.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of the company. Los Angeles Capital Management LLC acquired a new stake in shares of Bruker during the 4th quarter valued at about $26,000. Parallel Advisors LLC increased its position in shares of Bruker by 121.0% during the 4th quarter. Parallel Advisors LLC now owns 875 shares of the medical research company’s stock worth $41,000 after purchasing an additional 479 shares in the last quarter. Allworth Financial LP increased its holdings in shares of Bruker by 40.6% during the third quarter. Allworth Financial LP now owns 890 shares of the medical research company’s stock worth $29,000 after buying an additional 257 shares in the last quarter. Summit Securities Group LLC bought a new position in shares of Bruker in the fourth quarter valued at approximately $50,000. Finally, Parkside Financial Bank & Trust grew its position in Bruker by 144.6% during the 4th quarter. Parkside Financial Bank & Trust now owns 1,482 shares of the medical research company’s stock worth $70,000 after acquiring an additional 876 shares during the last quarter. Institutional investors own 79.52% of the company’s stock.

About Bruker

Bruker Corporation, founded in 1960 by physicist Günther Laukien and headquartered in Billerica, Massachusetts, is a leading developer and manufacturer of high-performance scientific instruments and analytical solutions. The company designs systems that enable molecular and materials research across academic, governmental, and industrial laboratories.

Bruker’s product portfolio encompasses nuclear magnetic resonance (NMR) spectrometers for molecular structure and dynamics studies, mass spectrometry platforms for proteomics and metabolomics, X-ray diffraction and scattering instruments for crystallography and materials characterization, atomic force and scanning probe microscopes for nanoscale surface analysis, as well as preclinical imaging systems such as micro-CT and MRI scanners.

In addition to hardware, Bruker provides software suites, applications support, training services, and long-term maintenance agreements to ensure optimal instrument performance.